Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Winter, Hauke ^a,b   van den Engel, Natasja K ^b   Poehlein, Christian H ^a   Hatz, Rudolf A ^b   Fox, Bernard A ^a,c   Hu, Hong Ming ^a,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; HYBRID PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN BETA RECEPTOR FC FUSION PROTEIN; PERFORIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2; RECOMBINANT LYMPHOTOXIN ALPHA1BETA2; UNCLASSIFIED DRUG; FC RECEPTOR; LIGAND; LYMPHOTOXIN ALPHA BETA; RECOMBINANT PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VIVO STUDY; KNOCKOUT GENE; LUNG METASTASIS; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MELANOMA; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; HUMAN; IMMUNOLOGY; MACROPHAGE; MOUSE MUTANT; NEOPLASM; PATHOLOGY; SERODIAGNOSIS; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LIGANDS; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; LYMPHOTOXIN BETA RECEPTOR; MACROPHAGES; MICE; MICE, KNOCKOUT; NEOPLASMS; NEUTRALIZATION TESTS; RECEPTORS, FC; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33947718021     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-14     Document Type: Article

References (48)

1. Dudley ME Wunderlich JR Robbins PF Yang JC Hwu P Schwartzentruber DJ Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 850-854 1764179 12242449 10.1126/science.1076514
2. Yee C Thompson JA Byrd D Riddell SR Roche P Celis E Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 2002 99 16168-16173 138583 12427970 10.1073/pnas.242600099
3. Winter H Hu HM Urba WJ Fox BA Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/ CD95L) J Immunol 1999 163 4462-4472 10510388
4. Winter H Hu HM McClain K Urba WJ Fox BA Immunotherapy of melanoma: A dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy J Immunol 2001 166 7370-7380 11390488
5. Poehlein CH Hu HM Yamada J Assmann I Alvord WG Urba WJ TNF plays an essential role in tumor regression after adoptive transfer of perforin/ IFN-gamma double knockout effector T cells J Immunol 2003 170 2004-2013 12574370
6. Kaplan DH Shankaran V Dighe AS Stockert E Aguet M Old LJ Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice Proc Natl Acad Sci USA 1998 95 7556-7561 22681 9636188 10.1073/pnas.95.13.7556
7. Shankaran V Ikeda H Bruce AT White JM Swanson PE Old LJ IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 2001 410 1107-1111 10.1038/35074122 11323675
8. Ikeda H Old LJ Schreiber RD The roles of IFN gamma in protection against tumor development and cancer immunoediting Cytokine Growth Factor Rev 2002 13 95-109 10.1016/S1359-6101(01)00038-7 11900986
9. Barth RJJ Mule JJ Spiess PJ Rosenberg SA Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes J Exp Med 1991 173 647-658 10.1084/ jem.173.3.647 1900079
10. Hu HM Urba WJ Fox BA Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile J Immunol 1998 161 3033-3041 9743368
11. Aruga A Aruga E Cameron MJ Chang AE Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression J Leukoc Biol 1997 61 507-516 9103238
12. Aruga A Aruga E Tanigawa K Bishop DK Sondak VK Chang AE Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role J Immunol 1997 159 664-673 9218581
13. Aruga A Shu S Chang AE Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells Cancer Immunol Immunother 1995 41 317-324 10.1007/BF01517220 8536278
14. Winter H Hu HM Poehlein CH Huntzicker E Osterholzer JJ Bashy J Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies Immunology 2003 108 409-419 1782899 12603608 10.1046/j.1365-2567.2003.01596.x
15. Peng L Krauss JC Plautz GE Mukai S Shu S Cohen PA T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics J Immunol 2000 165 7116-7124 11120842
16. Plautz GE Mukai S Cohen PA Shu S Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors J Immunol 2000 165 3656-3662 11034369
17. Browning JL Ngam-ek A Lawton P DeMarinis J Tizard R Chow EP Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface Cell 1993 72 847-856 10.1016/ 0092-8674(93)90574-A 7916655
18. Ware CF VanArsdale TL Crowe PD Browning JL The ligands and receptors of the lymphotoxin system Curr Top Microbiol Immunol 1995 198 175-218 7774281
19. Gramaglia I Mauri DN Miner KT Ware CF Croft M Lymphotoxin alphabeta is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation J Immunol 1999 162 1333-1338 9973387
20. Zhai Y Guo R Hsu TL Yu GL Ni J Kwon BS LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer J Clin Invest 1998 102 1142-1151 509097 9739048
21. Mauri DN Ebner R Montgomery RI Kochel KD Cheung TC Yu GL LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator Immunity 1998 8 21-30 10.1016/ S1074-7613(00)80455-0 9462508
22. Rooney IA Butrovich KD Glass AA Borboroglu S Benedict CA Whitbeck JC The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells J Biol Chem 2000 275 14307-14315 10.1074/ jbc.275.19.14307 10799510
23. Browning JL Miatkowski K Sizing I Griffiths D Zafari M Benjamin CD Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines J Exp Med 1996 183 867-878 10.1084/ jem.183.3.867 8642291
24. Hehlgans T Mannel DN Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion and growth arrest in A375 melanoma cells J Interferon Cytokine Res 2001 21 333-338 10.1089/107999001300177529 11429164
25. Crowe PD VanArsdale TL Walter BN Ware CF Hession C Ehrenfels B A lymphotoxin-beta-specific receptor Science 1994 264 707-710 10.1126/ science.8171323 8171323
26. Force WR Walter BN Hession C Tizard R Kozak CA Browning JL Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression J Immunol 1995 155 5280-5288 7594541
27. Murphy M Walter BN Pike-Nobile L Fanger NA Guyre PM Browning JL Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues Cell Death Differ 1998 5 497-505 10.1038/ sj.cdd.4400374 10200501
28. Degli-Esposti MA Davis-Smith T Din WS Smolak PJ Goodwin RG Smith CA Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells J Immunol 1997 158 1756-1762 9029113
29. Mackay F Browning JL Lawton P Shah SA Comiskey M Bhan AK Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis Gastroenterology 1998 115 1464-1475 10.1016/S0016-5085(98)70025-3 9834274
30. Probert L Eugster HP Akassoglou K Bauer J Frei K Lassmann H TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease Brain 2000 123 2005-2019 10.1093/brain/123.10.2005 11004118
31. Guo Z Wang J Meng L Wu Q Kim O Hart J Cutting edge: Membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection J Immunol 2001 167 4796-4800 11673481
32. Wu Q Salomon B Chen M Wang Y Hoffman LM Bluestone JA Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor J Exp Med 2001 193 1327-1332 10.1084/ jem.193.11.1327 11390440
33. Lucas R Tacchini-Cottier F Guler R Vesin D Jemelin S Olleros ML A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection Eur J Immunol 1999 29 4002-4010 10.1002/ (SICI)1521-4141(199912)29:12<4002::AID-IMMU4002>3.0.CO;2-S 10602010
34. Tamada K Shimozaki K Chapoval AI Zhai Y Su J Chen SF LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response J Immunol 2000 164 4105-4110 10754304
35. Yu KY Kwon B Ni J Zhai Y Ebner R Kwon BS A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis J Biol Chem 1999 274 13733-13736 10.1074/ jbc.274.20.13733 10318773
36. Shaikh RB Santee S Granger SW Butrovich K Cheung T Kronenberg M Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction J Immunol 2001 167 6330-6337 11714797
37. Tamada K Shimozaki K Chapoval AI Zhu G Sica G Flies D Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway Nat Med 2000 6 283-289 10.1038/ 73136 10700230
38. Schrama D thor Straten P Fischer WH McLellan AD Brocker EB Reisfeld RA Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue Immunity 2001 14 111-121 10.1016/S1074-7613(01)00094-2 11239444
39. Fu YX Chaplin DD Development and maturation of secondary lymphoid tissues Annu Rev Immunol 1999 17 399-433 10.1146/ annurev.immunol.17.1.399 10358764
40. Ansel KM Ngo VN Hyman PL Luther SA Forster R Sedgwick JD A chemokine-driven positive feedback loop organizes lymphoid follicles Nature 2000 406 309-314 10.1038/35018581 10917533
41. Yu P Lee Y Liu W Chin RK Wang J Wang Y Priming of naive T cells inside tumors leads to eradication of established tumors Nat Immunol 2004 5 141-149 10.1038/ni1029 14704792
42. Gerszten RE Garcia-Zepeda EA Lim YC Yoshida M Ding HA Gimbrone MAJ MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions Nature 1999 398 718-723 10.1038/19546 10227295
43. Tesch GH Maifert S Schwarting A Rollins BJ Kelley VR Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice J Exp Med 1999 190 1813-1824 10.1084/jem.190.12.1813 10601356
44. Huo Y Weber C Forlow SB Sperandio M Thatte J Mack M The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium J Clin Invest 2001 108 1307-1314 209441 11696575 10.1172/JCI200112877
45. Arca MJ Krauss JC Aruga A Cameron MJ Shu S Chang AE Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor Cancer Gene Ther 1996 3 39-47 8785710
46. Galon J Costes A Sanchez-Cabo F Kirilovsky A Mlecnik B Lagorce-Pages C Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 1960-1964 10.1126/ science.1129139 17008531
47. Dave SS Wright G Tan B Rosenwald A Gascoyne RD Chan WC Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 2004 351 2159-2169 10.1056/ NEJMoa041869 15548776
48. Zhang L Conejo-Garcia JR Katsaros D Gimotty PA Massobrio M Regnani G Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 2003 348 203-213 10.1056/NEJMoa020177 12529460